Board of Directors

The ICCR Board of Directors comprises representatives from each of it’s member organisations.

The ICCR Board has strategic oversight of all ICCR operations and financial and legal responsibility for the running of the ICCR and is governed by a charter.

John R Srigley

President

Dr John R Srigley, MD, FRCPC, FRCPath, FRCPA [Hon.]
Consultant in Oncological and Urological Pathology

Dr Srigley is a graduate of the Faculty of Medicine, University of Toronto. Following oncological pathology training at the University of Toronto and MD Anderson Cancer Centre in Houston, Dr Srigley was Director of Surgical Pathology at Sunnybrook Health Science Center and Chief of Laboratory Medicine at the Credit Valley Hospital. Currently he is the Chief and Medical Director of the Program of Laboratory Medicine and Genetics at Trillium Health Partners, one of the largest community-academic hospitals in Canada and also a Professor in the Department of Pathology and Molecular Medicine at McMaster University.

Dr Srigley is an international consultant and educator in the fields of oncological and urological pathology and has contributed extensively to the literature. He is an editor/author of three textbooks on urological pathology including the series 3 AFIP Fascicle on Tumors of the Prostate Gland. Dr Srigley has been an author and member of the international working groups for the 2004 and 2016 WHO Blue Books on Tumors of the Urinary System and Male Genital Organs. His research interests include clinical-pathological and translational studies of urological cancer, population-level quality initiatives in cancer pathology and the role of the pathologist in cancer control. Dr Srigley is a Past President of the International Society of Urological Pathologists (ISUP) and the Ontario Association of Pathologists.

Dr Srigley is the Expert Lead for Pathology and Chair of the National Pathology Standards Committee at the Canadian Partnership Against Cancer (CPAC) and represents Canada on the American Joint Committee on Cancer (AJCC).   Dr Srigley has championed the role of Pathologist as Diagnostic Oncologist and is a strong advocate for population-level standardized synoptic pathology reporting. Dr Srigley was the inaugural Head of Pathology and Laboratory Medicine at Cancer Care Ontario (2004-2013) and led the clinical implementation of discrete data field synoptic pathology reporting in Ontario. Working with the National Pathology Standards Committee and the Canadian Association of Pathologists, Dr Srigley was a key leader in securing formal endorsement of the College of American Pathologists(CAP) cancer checklists as pan-Canadian content standards for cancer pathology reporting. He is also a founding board member of the International Collaboration on Cancer Reporting (ICCR) and has provided advice on population-level standardized cancer reporting to CAP, the RCPA Structured Cancer Pathology Reporting Project in Australiasia as well as groups in Poland, Norway and Brazil.

James Kench

Vice-President

Professor James Kench, MB BS, BSc(Med), FRCPA.

Professor James Kench, MB BS, DMedSc, FRCPA, graduated in medicine from the University of Sydney in 1986. He commenced training in anatomical pathology in 1988 at Westmead Hospital then completed his training at Prince of Wales Hospital, Sydney NSW, before being awarded his Fellowship of the Royal College of Pathologists of Australasia in 1993. He is also a member of the International Academy of Cytology and International Fellow of the College of American Pathologists.

After working as a staff specialist at St Vincent’s and Westmead Hospitals, in 2009 Professor Kench became Clinical Director of Tissue Pathology and Diagnostic Oncology (formerly Anatomical Pathology) at Royal Prince Alfred Hospital in Sydney, where he is currently also Local Pathology Director-RPA. He was appointed as a Clinical Professor at University of Sydney in 2009 and has subspecialty expertise in prostatic, pancreatic and hepatic pathology. Professor Kench has published over 200 peer-reviewed journal articles plus several books and book chapters, including co-authorship of the Prostate Cancer chapter in the 2022 WHO Blue Book for Urinary and Male Genital Tumours. He has a longstanding research collaboration with the Prostate Cancer Group at the Garvan Institute of Medical Research and is an Executive member of the Australian Prostate Cancer Research Centre-NSW.

Professor Kench has been actively involved in structured reporting initiatives since 2008, including as lead author for the national pathology guidelines on prostate cancer, Chair of the National Structured Pathology Reporting Project for 4 years from 2014, member of the ICCR Dataset Steering Committee for 8 years and ICCR Board for 4 years. He is also a member of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Scientific Advisory Committee, the Australian Upper Gastrointestinal Cancer Registry Steering Committee and its Hepatobiliary Subcommittee, and the NSW Cancer Council Prostate and Colorectal Cancer Expert Advisory Panels.

Tim Helliwell

Executive Officer

Professor Tim Helliwell, MD, MB, BChir, FRCPath.
Consultant Histopathologist
Clinical Director for Cellular Pathology

Professor Tim Helliwell, MD, MB, BChir, FRCPath, graduated in medicine at the University of Cambridge and undertook his training in histopathology in the university Department of Pathology in Liverpool. 1984-2022 was Consultant Histopathologist at the Royal Liverpool University Hospital, Clinical Director for Cellular Pathology in Liverpool Clinical Laboratories and Honorary Professor of Pathology, University of Liverpool.

As a Consultant Histopathologist in Liverpool for 38 years, Professor Helliwell has a wide experience in diagnostic work. In 1997 the Department introduced specialist reporting and he has been lead histopathologist for head and neck, thyroid, bone, soft tissue and skeletal muscle pathology. Professor Helliwell regularly undertake undergraduate and post-graduate teaching in these areas.

Professor Helliwell’s MD thesis involved studies of techniques to demonstrate damage to skeletal muscle. He is an author or co-author of over 146 publications, and has contributed to chapters of the current revision of the WHO Classification of Tumours of the Head and Neck. Research interests were in the molecular pathology of head and neck cancer and soft tissue sarcomas, and in evidence-based pathology, particularly for head and neck cancer.

Professor Helliwell was the lead author for the national pathology guidelines for head and neck cancer published by the Royal College of Pathologists, and was a member of the NICE editorial board for the Improving Outcomes Guidance for Head and Neck Cancer. He helped to shape the development of cancer pathology datasets as Chair of the Cancer Services Working Group of the Royal College of Pathologists (2005-9). Professor Helliwell was sub-specialty adviser in ENT Pathology (2008-2012) to the Royal College of Pathologists and lead pathologist on the head and neck cancer site specific group of the National Cancer Intelligence Network and lead pathologist for review of national cancer dataset (2009-2012). He was an elected member of Council of the Royal College of Pathologists (2012-2014), leading on quality and performance indicators, and was elected Vice President of the Royal College of Pathologists (2014-2017) with responsibilities for training, assessments, examinations and research.

Professor Helliwell was invited to represent the Royal College on the Board of ICCR in 2016 and was elected Vice-President in 2017 (to Jan. 2022). He has been directly involved in writing the ICCR Head and Neck Cancer datasets and chaired the ICCR Dataset Steering Committee, providing quality assurance for the output. He has contributed regularly to international meetings on datasets under the auspices of ICCR, as well as contributing to meetings of the WHO International Association for Research into Cancer (IARC) and the UICC TNM committee. As Executive Officer, he continues to advise on and support the work of ICCR.

Thomas Wheeler

Director

Dr Thomas Wheeler, MD.
W.L. Moody, Jr. Professor of Pathology
Chair of the Department of Pathology & Immunology

Dr Thomas Wheeler, MD, is board certified in Anatomic Pathology, Clinical Pathology, and Cytopathology and has served over 40 years in academic, consultative, and director/clinical roles with leading University medical centers and healthcare enterprises.

Dr Wheeler received his medical degree with high honors from Baylor College of Medicine in Houston, Texas, in 1977. At Baylor College of Medicine and Affiliated Hospitals, he completed his residency in Anatomic and Clinical Pathology functioning as Chief Resident in Pathology. For over 40 years, Dr Wheeler served on the faculty at Baylor in the Departments of Pathology & Immunology and Urology and was Chair of the Department of Pathology & Immunology from 2004-2019.  In 2021 he was appointed to Distinguished Emeritus Professor and presently serves as Director of Surgical Pathology and Cytopathology at Sagis Diagnostics, PLLC.

Dr Wheeler has been a dedicated and outstanding teacher of residents, fellows and medical students serving for many years as a lecturer in the second year Pathology Medical School Course at Baylor College of Medicine.  He has served as Chief of Pathology at Ben Taub General Hospital and following that, at Baylor St. Luke’s Medical Center.

Along with his many faculty roles, Dr Wheeler‘s expertise in pathology, particularly genitourinary pathology, is reflected in his membership on Editorial Boards for Human Pathology, Prostate, American Journal of Surgical Pathology, Medscape Pathology & Laboratory Medicine and Archives of Pathology and Laboratory Medicine. He is also Editor-in-Chief of eMedicine’s online textbook of Pathology and Laboratory Medicine

Dr Wheeler has been an avid clinical researcher with special interests in studies related to diagnosis and prognosis in prostate cancer- his research has anchored the Pathology Department’s role in Baylor College of Medicine’s highly acclaimed prostate cancer program for many years. Since 1992, he has been involved on major research grants totaling over $750,000 including his involvement as the Director of the Pathology Core for Baylor College of Medicine’s Prostate SPORE grant.

Dr Wheeler has participated on numerous advisory boards and committees for both academic and industry related institutions. He is a well known author and lecturer with 350 publications and 60 speaker invitations. He has also served as a participant, committee member, and/or officer to a large number of national groups, programs and societies, including the College of American Pathologists, American Society for Clinical Pathology, US and Canadian Academy of Pathology, and the Texas Society of Pathologists.

James L Wisecarver

Director

Dr. James L Wisecarver, MD, PhD, FASCP.
Medical Director, Nebraska Medical Center Clinical Laboratories Omaha, Nebraska, USA
Vice Chair for Clinical Affairs and as Medical Director for the Clinical Laboratories at The Nebraska Medicine
Director of the Human DNA Identification Laboratory at UNMC

Dr James L Wisecarver, MD, PhD, FASCP, received his doctor of medicine degree from the University of Nebraska Medical Center (UNMC), Omaha, Neb. Dr Wisecarver earned a bachelor’s degree in biology from Doane College, Crete, Neb., and a doctorate degree in physiology from Creighton University, Omaha. He completed a residency in combined anatomic and clinical pathology at the University of Nebraska Medical Center and then joined the faculty in the Department of Pathology/Microbiology at UNMC as an Assistant Professor in 1990. He was promoted to Associate Professor in 1995 and to Professor in 2002. Currently, he serves as Vice Chair for Clinical Affairs and as Medical Director for the Clinical Laboratories at The Nebraska Medicine. He also serves as the Director of the Human DNA Identification Laboratory at UNMC.

Dr Wisecarver is currently President-elect of the American Society for Clinical Pathology (ASCP) Board of Directors. “My involvement in ASCP activities dates back to the Council on Continuing Education (CCE) when I became active with the section on diagnostic immunology and molecular pathology. Later, I was elected to the Board of Governors of the ASCP Board of Registry (now Board of Certification). While serving on the Board, I helped organize a new examination committee to develop the molecular biology examination and associated credential that is now being offered through the ASCP Board of Certification.” Dr. Wisecarver has also been a member of the ASCP Commission on Science, Technology and Public Policy, the Fellow Council, and the Pathologists Workforce Task Force. He has also chaired the Awards Committee.

Dr Wisecarver has organized and presented molecular diagnostics workshops offered both through ASCP and the United States and Canada Academy of Pathology (USCAP).

Recently, Dr Wisecarver celebrated 44 years of marriage with his wife, Patty. They have two grown children and four grandchildren. He enjoys spending time with the grandchildren, along with golfing, fishing and hunting.

Kieran Sheahan

Director

Professor Kieran Sheahan, MB, BCh, BAO, BSc, FRCPI, FFPath, FCAP, FFRCPath.
Consultant Histopathologist at St. Vincent's University Hospital (SVUH), Dublin
Clinical Professor at University College Dublin School of Medicine

Professor Kieran Sheahan, MB, BCh, BAO.,B.Sc.,FRCPI, FFPath, FCAP, FFRCPath,  is a Consultant Histopathologist at St. Vincent’s University Hospital (SVUH), Dublin  and is Full Clinical Professor at University College Dublin School of Medicine. He trained at the Mallory Institute of Pathology, Boston, where he is Adjuvant Professor of Pathology at Boston University Medical School. He is a Director of the Centre for Colorectal Disease, SVUH. He is the Chair of the Histopathology steering committee for the Irish National ‘BowelScreen’ programme.  He is former Treasurer  & President of the Irish Society of Surgical Pathology (ISSP). He is currently on the Board of the International Collaboration on Cancer Reporting (ICCR).

His research interests include prognostic & predictive markers in colorectal cancer, familial gastrointestinal cancer, and application of immunohistochemical & molecular genetic techniques in pathology. He has numerous collaborations internationally. He is author of over 180 original publications in peer-reviewed biomedical journals, & numerous reviews & book chapters. He is co-editor of the upcoming Morson & Dawson’s Gastrointestinal Pathology (6th edition).

Peter Schirmacher

Director

Professor Peter Schirmacher
Director of the Institute of Pathology (IPH) of Heidelberg University (Germany)
Chairman of the German Society of Pathology and Council Member of the European Association of Pathology
Board member of the National Center of Tumor Diseases

Professor Peter Schirmacher is Director of the Institute of Pathology (IPH) of Heidelberg University (Germany) since 2004, Chairman of the German Society of Pathology and Council Member of the European Association of Pathology, Board member of the National Center of Tumor Diseases, member of the German Academy of Sciences Leopoldina, honorary member of the Hungarian Academy of Sciences, and Principle Investigator in many national and international consortia.

Professor Schirmacher studied Medicine at Mainz University (Germany) and Molecular Biology at Albert Einstein College, New York, received training and board certification in Pathology and Molecular Pathology at Mainz University and was Professor of Pathology at Cologne University from 1998 until 2004.

Professor Schirmacher’s scientific interest centers on liver and molecular pathology with specific emphasis on molecular pathogenesis of hepatobiliary cancer; he has contributed to over 600 publications and numerous guidelines mainly centering on these topics.  Professor Schirmacher is coordinator of the Coordinative Research Center ‘Liver Cancer’ of the German Research Foundation involving three University Centers and about 50 Researchers. IPH is Center of Excellence of the ESP for Liver and Molecular Pathology.

Katia Ramos Moreira Leite

Director

Dr Katia Ramos Moreira Leite, MD, PhD.
Associated Professor and Chairman of the Laboratory of Medical Investigation of the University of Sao Paulo Medical School, Brazil
Vice-President and President-Elected of the Brazilian Society of Pathology

Dr Katia Ramos Moreira Leite, MD, PhD is Associated Professor and Chairman of the Laboratory of Medical Investigation of  the University of Sao Paulo Medical School in Sao Paulo, Brazil.

Dr Leite is President of the Brazilian Society of Pathology for the term 2020-2022. Standing Member of WHO/IARC Blue books 2022-2024 and councilor for South America of the International Society of Urological Pathology (ISUP) from 2015 to 2019.

Dr Leite is Associate Editor of the journal Surgical and Experimental Pathology and member of the Editorial Board of Pathology Journal, Modern Pathology, Journal of Carcinogenesis and International Brazilian Journal of Urology.

Dr Leite has 460 publications in peer reviewed journal articles plus several book chapters.

Annie Nga-Yin Cheung

Director

Professor Annie Nga-Yin Cheung, MD, PhD.
Laurence L T Hou Professorship in Anatomical Molecular Pathology and Clinical Professor at the Department of Pathology, The University of Hong Kong (HKU)
Director of the HKU Cervical Cytology Laboratory and the University Pathology Laboratory (Molecular Pathology)
Chief of Service of Pathology, HKU-Shenzhen Hospital

Professor Annie Nga-Yin Cheung is Laurence L T Hou Professorship in Anatomical Molecular Pathology and Clinical Professor at the Department of Pathology, The University of Hong Kong (HKU). She is the key pathologist for gynecological histopathology and cytology in Queen Mary Hospital, Director of the HKU Cervical Cytology Laboratory and the University Pathology Laboratory (Molecular Pathology) as well as the Chief of Service of Pathology, HKU-Shenzhen Hospital.

Professor Cheung was a HKU MBBS graduate and continued her studies at HKU for her MD and PhD. She received her postgraduate gynecological pathology training in the University of Manchester, UK, Massachusetts General Hospital, Harvard Medical School and The Armed Forces Institute of Pathology, USA. Professor Cheung’s research focuses on ovarian, endometrial and cervical cancers as well as gestational trophoblastic disease, aiming at investigating diagnostic and prognostic markers as well as molecular targets for better therapy. Professor Cheung has received awards on education and research. She has over 250 publications and has contributed to chapters in the WHO Classification of Tumours of Female Reproductive Organs.

Professor Cheung is currently Standing Member, Editorial Board of 5th Edition WHO Classification of Tumours, Commissioner, Lancet Commission on Diagnostics and Chairman, Credentials and Appeals Committee, The Hong Kong College of Pathologists. She is also the Advisor to Executive Board, Asian Oceania Research on Genital Infections and Neoplasia and Immediate Ex-President of The Hong Kong College of Pathologists. Professor Cheung has been President of Hong Kong Society for Colposcopy and Cervical Pathology as well as Council Member of the International Federation for Cervical Pathology and Colposcopy and Council Member at Large of the International Society of Gynaecological Pathologists.

Gerald Hoefler

Director

Professor Gerald Hoefler.
Professor for Pathology and Director of the Diagnostic and Research Institute of Pathology of the Medical University of Graz (Austria)
Chairman of the Working Group for Molecular Pathology, European Society for Pathology (ESP)

Professor Gerald Hoefler is Professor for Pathology and Director of the Diagnostic and Research Institute of Pathology of the Medical University of Graz (Austria) since 2008. He was President of the Austrian Society of Pathology (ÖGPath) 2016-18 and is currently Chairman of the Working Group for Molecular Pathology, European Society for Pathology (ESP).

Professor Hoefler was a Board Member on the Austrian Science Foundation (FWF) 2007-14 and is a member of the Senate of the Medical University of Graz since 2009. He is the Director of the FWF funded Doctoral College Metabolic and Cardiovascular Disease since 2010.

Professor Hoefler studied Medicine at the Karl-Franzens-University Graz (Austria). He received an Erwin-Schrödinger fellowship of the Austrian Science Foundation (FWF), which he spent at the Kennedy Institute for Handicapped Children, Johns Hopkins School of Medicine, Baltimore, MD, USA (1986-88) and an Otto Loewi fellowship which he spent at the Department of Medical Biochemistry, University of Graz (1989-90). Professor Hoefler received training and board certification (1995) in Laboratory Medicine and in Pathology and Genetics (1997) at the Karl-Franzens-University Graz.

His particular scientific interest focuses on molecular pathology, neoplasia and lipid metabolism. Recently, his research group investigates the effects of tumour growth on triglyceride metabolism. During the last five years Professor Hoefler has been awarded over 4 Million € in competitive 3rd party funding. He has published 238 papers listed in SCI/SSCI and/or PUBMED with a combined IF of 1166 that have been cited >9100 times. His current H-index is 53.

Holger Moch

Director

Professor Holger Moch.
Board certified in Pathology and in Molecular Pathology
Professor of Pathology at the University Zurich
Chairman of the Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland

Professor Holger Moch graduated from Humboldt University Berlin (Charité), Germany. He obtained postgraduate qualifications at the University Hospital Basel, Switzerland and is board certified in Pathology and in Molecular Pathology.

Currently, Holger Moch is Professor of Pathology at the University Zurich and Chairman of the Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland. Since 2016, he is an associate member of the Department of Biology at the Swiss Federal Institute of Technology (ETH).

Professor Moch developed a robust translational research program to understand the molecular background of urogenital tumours. His work is described in more than 500 peer-reviewed papers (H-Index 97). He edited the 2016 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs “WHO blue book” and is now an editorial board standing member of the WHO Classification of Tumours (5th Edition).

Professor Moch is member of the German National Academy of Science Leopoldina, the Swiss Academy of Medical Sciences and Past President of the European Society of Pathology.

Toyonori Tsuzuki

Director

Dr Toyonori Tsuzuki, MD, PhD
Chair of Department of Surgical Pathology (Japan)
Vice President of Aichi Medical University Hospital (Japan)

Dr Toyonori Tsuzuki, MD, PhD is full professor of Surgical Pathology at Aichi Medical University (Japan). He graduated in 1989 and obtained Ph.D. in 1994 at Nagoya University School of Medicine (Japan). He is board certified in Pathology, in Molecular Pathology, and in Cytopathology.

Dr Tsuzuki is the Chair of department of Surgical Pathology and then a Vice president of Aichi Medical University Hospital, one of the largest community-academic hospitals in Japan.

His research interest focuses on diagnostic and digital pathology, with a specific emphasis on oncology. Professor Tsuzuki is author of over 200 original publications in peer-reviewed biomedical journals and has contributed to chapters in the WHO Classification of Urinary System and Male Genital Organs. His major interests are diagnostic pathology and oncology based on pathological findings. He is also interested in artificial intelligence in pathology.

Dr Tsuzuki is the President of the Japanese Society of Urological Pathology. He is also the President-Elected of the International Academy of Pathology. Japanese division for the term 2022-2025, Executive Director of the Japanese Society of Pathology, Executive Director of the Japanese Society of Clinical Cytology, Councilor of the Japanese Society of Urologic Oncology, Councilor for Asia the International Society of Urological Pathology (ISUP).

Anna Sapino

Director

Dr Anna Sapino, MD.
Full professor of Surgical Pathology at the University of Torino (Italy)
Director of the Surgical Pathology Unit and Scientific Director of the Institute of Cancer Research (FPO-IRCCS) of Candiolo (Italy)
Director of the Department of Medical Sciences, University of Torino (Italy)

Dr Anna Sapino, MD is full professor of Surgical Pathology at the University of Torino (Italy). She graduated at the Faculty of Medicine, University of Torino, and specialized in Surgical Pathology at the University of Milano (Italy).

Dr Sapino was Director of the Surgical Pathology Unit and then Director of the Department of Laboratory Medicine at Città della Salute e della Scienza di Torino, one of the largest community-academic hospitals in Italy. Presently she is the Director of the Surgical Pathology Unit and Scientific Director of the Institute of Cancer Research (FPO-IRCCS) of Candiolo (Italy) and also, Director of the Department of Medical Sciences, University of Torino (Italy).

She has been Chair del European Working Group for Breast Cancer Pathology and she President of the Italian Society of Pathology and Cytology (SIAPeC)  for the three-year period 2019-2022

Dr Sapino has been an author and member of the international working groups for the 2012 and 2019 WHO Blue Books of tumors of the breast. She leads a well-consolidated research group in breast pathology and can count on the collaboration of basic and clinical scientists with different cultural backgrounds. The results of her studies have been presented to National and International Meetings and published on peer-reviewed international journals. She has lectured extensively at national and international meetings.

Dr Sapino has been awarded by of the Vladimir Totović price  by the  German Division of IAP and nominated in The Pathologist Power List 2020 – A Solid Foundation for educators and mentors.

Dr Sapino has been nominated in The Pathologist Power List 2020 – A Solid Foundation for educators and mentors.

Vyacheslav Grinevich

Director

Dr Vyacheslav Grinevich, MD, PhD.
Consultant in Oncological Pathology
Head of the Department of Oncopathology of the Moscow Research Oncological Institute
Head of the Department of Pathology of the Moscow Clinical Scientific Center
President of the Russian Society of Oncopathology (RSOP)
Chairman of the Working Group for Cancer Reporting of the Russian Society of Oncopathology

Dr Grinevich graduated from the Medical Faculty of the Omsk State Medical Academy. Following oncological pathology training at the Department of Pathology of the Omsk State Medical Academy, Dr Grinevich was employed more than 20 years as a staff pathologist at the Department of Pathology of the Omsk Regional Oncological Center and the Moscow City Oncological Hospital No. 62, and then as a Head of the Department of Pathology of the Moscow City Oncological Hospital No. 62, and had subspecialty expertise in bone, thoracic and breast pathology.

Currently Dr Grinevich is a Head of the Department of Oncopathology of the Moscow Research Oncological Institute named after P. A. Herzen, which is a branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation. His research interests at the Herzen Institute include thoracic and breast pathology.

Dr Grinevich is also a Head of the Department of Pathology of the Moscow Clinical Scientific Center named after A. S. Loginov of the Department of Healthcare of Moscow, which was established on the basis of the Central Research Institute of Gastroenterology. His research interests at the Loginov Center include hepatopancreatobiliary and gastrointestinal pathology.

Dr Grinevich is President of the Russian Society of Oncopathology (RSOP) since 2016. He is one of the leading Russian experts in oncopathology and an active supporter of the standardization of pathology, including cancer reports and companion diagnostics. He is Chairman of the Working Group for Cancer Reporting of the Russian Society of Oncopathology.

Dr Grinevich is also Associate Editor of the Russian Journal of Oncopathology. He has over 100 publications in peer reviewed journal articles.

Zhiyong Liang

Director

Professor Zhiyong Liang, MD, PhD.
Director of the Department of Pathology and Molecular Pathology Research Center of Peking Union Medical College Hospital, Chinese Academy of Medical Science
Chairman of the Chinese Society of Pathology
Director of National Pathology Quality Control Center
Chairman of the Chinese Society of Pathology
Director of National Pathology Quality Control Center

Professor Zhiyong Liang, MD, PhD is Director of the Department of Pathology and Molecular Pathology Research Center of Peking Union Medical College Hospital, Chinese Academy of Medical Science since 2014, Chairman of the Chinese Society of Pathology, and Director of National Pathology Quality Control Center. He has been practicing anatomical pathology for thirty-one years.

Professor Liang subspecialties include molecular, breast, and endocrine pathology. He is Editorial Board Member of the journal Endocrine Pathology, Editor-in-Chief of Chinese Journal of Diagnostic Pathology and Associate Editor-in-Chief of Chinese Journal of Pathology.

His research interest focuses on molecular pathology and digital pathology, with specific emphasis on molecular mechanism of pancreatic carcinoma microenvironment. Professor Liang is author of over 150 original publications in peer-reviewed biomedical journals.

Vanessa Kääb-Sanyal

Director

Dr rer nat Vanessa Kääb-Sanyal
Director
Professional Association of German Pathologists (BDP)

Dr rer nat Vanessa Kääb-Sanyal is the Director of the Professional Association of German Pathologists (BDP).

As trained mathematician and former managing Director of the Kooperationsgemeinschaft Mammographie (KoopG) Dr Kääb-Sanyal has profound expertise in developing specifications for uniform documentation and evaluation of screening services as well as establishing unified reporting procedures on a nationwide scale within a federal political system. Moreover, her experience with the implementation of the German breast cancer screening program and her insight in evaluating and interpreting its outcomes came to bear in several publications about screening effects and epidemiological findings.

Dr Kääb-Sanyal is a member of the executive board of the European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services (EUREF). Furthermore, Dr Kääb-Sanyal was a member of the evaluation board of the First Evaluation Report on the Austrian Breast Cancer Screening Programme and an associated member of the Quality Assurance Scheme Development Group of the European Commission Initiative on Breast Cancer.

Sanchia Aranda

Director*

Professor Sanchia Aranda.
President-elect of the Union for International Cancer Control

Professor Sanchia Aranda was appointed CEO of Cancer Council Australia in August 2015.

Professor Aranda has more than 30 years’ experience in cancer control as a clinician, researcher, educator and senior healthcare administrator.

From her early career as a Registered Nurse in New Zealand she specialised in cancer and palliative care, completing a Bachelor of Applied Science, a Master of Nursing and a doctoral thesis exploring nurse-patient relationships in cancer and palliative care. Her most recent role was Director of Cancer Services and Information and Deputy CEO at the Cancer Institute NSW.

Professor Aranda is President-elect of the Union for International Cancer Control (the world’s peak member-based cancer organisation) and a former President of the International Society of Nurses in Cancer Care.

As well as being a research fellow at the Peter MacCallum Cancer Centre, she holds academic appointments within the School of Health Sciences, University of Melbourne, and the Faculty of Nursing, University of Sydney.

From a digital technology perspective in her research work Professor Aranda has led studies utilising web and application based programs for support of patients, most recently a randomised trial of a remote symptom assessment system with real time health system connectivity. In her previous role at the Cancer Institute NSW she oversaw the development of technology initiatives in cancer registries including automation of data extracts from clinical information systems into the Central Cancer Registry in NSW. She has also been involved in initiatives to routinely collect patient reported outcomes into clinical information systems. In her CINSW role she established clinical data governance functions and ethical approvals for linked datasets.

In August 2015 she took up the role of CEO of Australia’s peak non-government cancer control organisation. In this role she is a strong independent voice on evidence-based cancer control. She is engaged in all fields of cancer from primary prevention through to survivorship and advanced care, and has a particular professional interest in improved ways to care for and support cancer patients and enhanced use of administrative datasets to understand clinical variation and to improve our cancer system.

She is a regular commentator on cancer issues in Australian media.

Professor Aranda’s role in cancer control has been recognised nationally and internationally, and in 2013 she was named the 4th Peter MacCallum Cancer Centre Distinguished Fellow for her contributions to cancer nursing. In 2016 she received the International Society of Nurses in Cancer Care’s Distinguish Merit Award for her contributions to cancer nursing.

*Note it is a requirement of Australian law that companies incorporating in Australia have 2 Australian resident directors.

By using this website, you acknowledge that you have read and understand the Privacy Policy. It appears you're using an old version of Internet Explorer for safer and optimum browsing experience please upgrade your browser.